A Phase 3 interventional study of Pregabalin and Pregabalin in Fibromyalgia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 102 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-25.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing pregabalin in Fibromyalgia — 6 open to participants now, 6 under way, none of them phase 3. Pregabalin · Fibromyalgia.
Among the 30 studies testing pregabalin in Fibromyalgia, this one is the 2nd largest by enrollment, is the only one that started in 2004, is one of 13 in phase 3, and was the 7th registered.
1,244 studies on the registry are indexed under Fibromyalgia; 255 are open to participants now.
Browse Fibromyalgia studies →6 of the 30 studies testing pregabalin in Fibromyalgia are open now, in 2 countries. Recruiting first, the newest first:
Beijing Tiantan Hospital · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18–65
By country, each count listing its studies:
Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 160 Fibromyalgia studies recruiting now, 50 (31%) set no upper age limit and 96 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 14 · Phase 4 7
First in 2004; this study’s year is marked. 1 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 751 is above the median of 60 across 938 interventional studies indexed under Fibromyalgia.
Median enrollment 199 across the 30 interventional studies. Of the 22 that completed or were terminated, 10 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 30 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
19 studies in Fibromyalgia by Viatris Inc.: none open now, none under way, none of them phase 3. Of 19 finished, 13 (68%) have results posted.
Among the 19 studies in Fibromyalgia by Viatris Inc., this one is the 2nd largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2004, is one of 13 in phase 3, and was the 7th registered.
Viatris Inc.’s Fibromyalgia studies by the year they started, since 2004.
4 of the studies testing pregabalin in Fibromyalgia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07186751Beijing Tiantan HospitalThe Efficacy and Safety of Pregabalin Combined With Venlafaxine in Patients With Fibromyalgia | 2027-06-30 |
| NCT07230197Beijing Tiantan HospitalThe Efficacy and Safety of Pregabalin Combined With Dexmedetomidine in Patients With Fibromyalgia | 2027-06-30 |
| NCT07208357Beijing Tiantan HospitalThe Efficacy and Safety of Pregabalin Combined With Toludesvenlafaxine in Patients With Fibromyalgia | 2027-06-30 |
| NCT07171320Beijing Tiantan HospitalThe Efficacy and Safety of Pregabalin Combined With Desvenlafaxine in Patients With Fibromyalgia | 2027-06-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 30 studies testing pregabalin in Fibromyalgia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Viatris Inc.’s 19 in Fibromyalgia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of pregabalin versus placebo for the symptomatic relief of pain associated with fibromyalgia. If this objective is met, then the second objective will be to evaluate the efficacy and safety of pregabalin versus placebo for the management of fibromyalgia (pain, patient global assessment, and functional status). Additionally, the study will evaluate the efficacy of pregabalin versus placebo to improve sleep, fatigue, and mood disturbance associated with fibromyalgia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Pregabalin
Drug: Pregabalin
Drug: Pregabalin
Drug: Placebo
Pregabalin 225 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
Pregabalin 150 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
Pregabalin 300 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
Matching placebo capsules taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
Endpoint mean pain score derived from the subject's daily pain diary
Time frame: Endpoint
Patient Global Assessment (Patient Global Impression of Change) at Termination Visit
Time frame: Weeks 5 and 13
Change from baseline in functioning (score created from the Short Form-36 [SF-36] Social and Physical Functioning, Fibromyalgia Impact Questionnaire [FIQ]-Total Score, and Sheehan Disability Scale [SDS] Total Score) at Termination Visit
Time frame: Baseline and Weeks 5, 9, and 13
Change from baseline in FIQ scores at Weeks 5, 9, and 13
Time frame: Baseline and Weeks 5, 9, and 13
Change from baseline in SDS scores at Weeks 5, 9, and 13
Time frame: Baseline and Weeks 5, 9, and 13
Change from baseline in Medical Outcomes Study (MOS)-Sleep Scale scores at Weeks 5, 9, and 13
Time frame: Baseline and Weeks 5, 9, and 13
Quality of Sleep Score from the Daily Sleep Diary
Time frame: Daily
Change from baseline in Multidimensional Assessment of Fatigue (MAF) scores at Weeks 5, 9, and 13
Time frame: Baseline and Weeks 5, 9, and 13
Change from baseline in Hospital Anxiety and Depression Scale (HADS) scores at Week 13
Time frame: Baseline and Week 13
Change from baseline in Short Form McGill Pain Questionnaire (SF-MPQ) scores at Weeks 5, 9, and 13
Time frame: Screening, baseline, and Weeks 5, 9, and 13
Change from baseline in Fibromyalgia Health Assessment Questionnaire (F-HAQ) scores at Weeks 9 and 13
Time frame: Baseline and Weeks 9 and 13
Adverse events
Time frame: Weeks 1, 2, 5, 9, 13, and at follow-up
Physical examination, including vital signs and weight
Time frame: Baseline and Week 5 (vital signs only) and 13
Neurological examination
Time frame: Screening and Week 13
Electrocardiogram
Time frame: Screening and Week 13
Laboratory tests, including chemistry and hematology
Time frame: Baseline and Weeks 5, 13, and at follow-up
Urinalysis
Time frame: Baseline and Weeks 13 and at follow-up
Showing the first 100 of 102 sites. Choose a country and city above to see the rest.
The record gives a start of Sep 2004 and a completion of Jun 2005. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pregabalin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →